|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: OGFOD1 |
Gene summary for OGFOD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | OGFOD1 | Gene ID | 55239 |
| Gene name | 2-oxoglutarate and iron dependent oxygenase domain containing 1 | |
| Gene Alias | TPA1 | |
| Cytomap | 16q13 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | Q8N543 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55239 | OGFOD1 | LZE2T | Human | Esophagus | ESCC | 3.23e-04 | 4.93e-01 | 0.082 |
| 55239 | OGFOD1 | LZE4T | Human | Esophagus | ESCC | 2.92e-14 | 4.15e-01 | 0.0811 |
| 55239 | OGFOD1 | LZE7T | Human | Esophagus | ESCC | 1.44e-04 | 2.19e-01 | 0.0667 |
| 55239 | OGFOD1 | LZE8T | Human | Esophagus | ESCC | 4.49e-05 | 6.32e-02 | 0.067 |
| 55239 | OGFOD1 | LZE20T | Human | Esophagus | ESCC | 4.69e-02 | 3.82e-02 | 0.0662 |
| 55239 | OGFOD1 | LZE24T | Human | Esophagus | ESCC | 6.22e-09 | 1.04e-01 | 0.0596 |
| 55239 | OGFOD1 | P1T-E | Human | Esophagus | ESCC | 3.24e-05 | 1.98e-01 | 0.0875 |
| 55239 | OGFOD1 | P2T-E | Human | Esophagus | ESCC | 7.79e-18 | 1.38e-01 | 0.1177 |
| 55239 | OGFOD1 | P4T-E | Human | Esophagus | ESCC | 1.58e-20 | 3.77e-01 | 0.1323 |
| 55239 | OGFOD1 | P5T-E | Human | Esophagus | ESCC | 1.42e-16 | 2.83e-01 | 0.1327 |
| 55239 | OGFOD1 | P8T-E | Human | Esophagus | ESCC | 8.65e-16 | 1.27e-01 | 0.0889 |
| 55239 | OGFOD1 | P9T-E | Human | Esophagus | ESCC | 2.85e-09 | 9.98e-02 | 0.1131 |
| 55239 | OGFOD1 | P10T-E | Human | Esophagus | ESCC | 6.08e-08 | 1.11e-01 | 0.116 |
| 55239 | OGFOD1 | P11T-E | Human | Esophagus | ESCC | 9.94e-12 | 3.51e-01 | 0.1426 |
| 55239 | OGFOD1 | P12T-E | Human | Esophagus | ESCC | 9.76e-18 | 2.96e-01 | 0.1122 |
| 55239 | OGFOD1 | P15T-E | Human | Esophagus | ESCC | 6.57e-11 | 2.36e-01 | 0.1149 |
| 55239 | OGFOD1 | P16T-E | Human | Esophagus | ESCC | 3.23e-08 | 1.46e-01 | 0.1153 |
| 55239 | OGFOD1 | P17T-E | Human | Esophagus | ESCC | 2.97e-08 | 2.43e-01 | 0.1278 |
| 55239 | OGFOD1 | P19T-E | Human | Esophagus | ESCC | 4.26e-05 | 5.58e-01 | 0.1662 |
| 55239 | OGFOD1 | P20T-E | Human | Esophagus | ESCC | 2.33e-23 | 3.02e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
| GO:0006417111 | Esophagus | ESCC | regulation of translation | 304/8552 | 468/18723 | 1.53e-17 | 1.33e-15 | 304 |
| GO:003298416 | Esophagus | ESCC | protein-containing complex disassembly | 151/8552 | 224/18723 | 3.45e-11 | 1.15e-09 | 151 |
| GO:001820816 | Esophagus | ESCC | peptidyl-proline modification | 46/8552 | 58/18723 | 1.59e-07 | 2.51e-06 | 46 |
| GO:003406315 | Esophagus | ESCC | stress granule assembly | 23/8552 | 26/18723 | 6.82e-06 | 6.90e-05 | 23 |
| GO:00181263 | Esophagus | ESCC | protein hydroxylation | 23/8552 | 27/18723 | 2.60e-05 | 2.19e-04 | 23 |
| GO:00432446 | Esophagus | ESCC | regulation of protein-containing complex disassembly | 75/8552 | 121/18723 | 2.17e-04 | 1.36e-03 | 75 |
| GO:00195114 | Esophagus | ESCC | peptidyl-proline hydroxylation | 13/8552 | 15/18723 | 1.31e-03 | 6.26e-03 | 13 |
| GO:00436245 | Esophagus | ESCC | cellular protein complex disassembly | 78/8552 | 136/18723 | 4.00e-03 | 1.62e-02 | 78 |
| GO:002241112 | Liver | HCC | cellular component disassembly | 282/7958 | 443/18723 | 1.02e-19 | 1.38e-17 | 282 |
| GO:000641722 | Liver | HCC | regulation of translation | 287/7958 | 468/18723 | 8.79e-17 | 8.08e-15 | 287 |
| GO:003298411 | Liver | HCC | protein-containing complex disassembly | 138/7958 | 224/18723 | 5.59e-09 | 1.46e-07 | 138 |
| GO:00340632 | Liver | HCC | stress granule assembly | 24/7958 | 26/18723 | 1.35e-07 | 2.57e-06 | 24 |
| GO:001820811 | Liver | HCC | peptidyl-proline modification | 42/7958 | 58/18723 | 3.73e-06 | 4.85e-05 | 42 |
| GO:00432444 | Liver | HCC | regulation of protein-containing complex disassembly | 66/7958 | 121/18723 | 4.94e-03 | 2.07e-02 | 66 |
| GO:0018126 | Liver | HCC | protein hydroxylation | 18/7958 | 27/18723 | 9.75e-03 | 3.66e-02 | 18 |
| GO:00436242 | Liver | HCC | cellular protein complex disassembly | 71/7958 | 136/18723 | 1.39e-02 | 4.95e-02 | 71 |
| GO:002241119 | Oral cavity | OSCC | cellular component disassembly | 283/7305 | 443/18723 | 9.57e-27 | 3.37e-24 | 283 |
| GO:000641720 | Oral cavity | OSCC | regulation of translation | 274/7305 | 468/18723 | 4.39e-18 | 4.63e-16 | 274 |
| GO:003298410 | Oral cavity | OSCC | protein-containing complex disassembly | 136/7305 | 224/18723 | 3.42e-11 | 1.13e-09 | 136 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| OGFOD1 | SNV | Missense_Mutation | rs752724033 | c.688N>T | p.Arg230Cys | p.R230C | Q8N543 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| OGFOD1 | SNV | Missense_Mutation | c.158T>C | p.Val53Ala | p.V53A | Q8N543 | protein_coding | tolerated(1) | benign(0) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| OGFOD1 | SNV | Missense_Mutation | novel | c.709N>G | p.Phe237Val | p.F237V | Q8N543 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-C8-A12X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| OGFOD1 | SNV | Missense_Mutation | novel | c.709T>G | p.Phe237Val | p.F237V | Q8N543 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D8-A1X7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | ChemotherapyHormone Therapy | doxorubicine+cyclophosphamide+tamoxifen | SD |
| OGFOD1 | SNV | Missense_Mutation | novel | c.709N>G | p.Phe237Val | p.F237V | Q8N543 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-E2-A14Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| OGFOD1 | SNV | Missense_Mutation | c.105G>C | p.Leu35Phe | p.L35F | Q8N543 | protein_coding | tolerated(0.29) | benign(0.007) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| OGFOD1 | SNV | Missense_Mutation | novel | c.1456N>A | p.Glu486Lys | p.E486K | Q8N543 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A959-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| OGFOD1 | insertion | Frame_Shift_Ins | novel | c.740_741insAGTG | p.Asn247LysfsTer5 | p.N247Kfs*5 | Q8N543 | protein_coding | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | ||
| OGFOD1 | insertion | In_Frame_Ins | novel | c.741_742insTGGGAT | p.Asn247_Tyr248insTrpAsp | p.N247_Y248insWD | Q8N543 | protein_coding | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | ||
| OGFOD1 | insertion | Frame_Shift_Ins | novel | c.740_741insAGTG | p.Asn247LysfsTer5 | p.N247Kfs*5 | Q8N543 | protein_coding | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |